Search Results

• A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)

  4202-HEM-301: An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral Etavopivat, a Pyruvate Kinase Activator in Patients With Sickle Cell Disease (HIBISCUS)

• A Study to Learn How Safe the Study Treatment BAY94-9027 is and How it Affects the Body in Previously Treated Children Aged 7 to Less Than 12 Years With Severe Hemophilia A

  21824 - A Phase 3, Single Group Treatment, Open-label, Study to Evaluate the Safety of BAY 94-9027 Infusions for Prophylaxis and Treatment of Bleeding in Previously Treated Children Aged 7 to <12 Years With Severe Hemophilia A

• Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

  A5481092 - Phase 1/2 study to evaluate Palbociclib (Ibrance®) in combination with Irinotecan and Temozolomide and/or in combination with Topotecan and Cyclophosphamide in pediatric patients with recurrent or refractory solid tumors

• DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma

  Phase II Trial of Eflornithine/DFMO as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma

• A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis

  An Open-Label, Single-Arm Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of Etrasimod in Adolescent Subjects with Moderately to Severely Active Ulcerative Colitis

• Children’s Brain Tumor Network (CBTN) Collection Protocol

  Children’s Brain Tumor Network (CBTN) Collection Protocol

• Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma

  Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma

• The Association of Kawasaki Disease and COVID-19 with Cardiac Complications:

  The Association of Kawasaki Disease and COVID-19 with Cardiac Complications: A Focused Sub-study of the International Kawasaki Disease Registry (IKDR)

• SurvivorLink: Scalability of an Electronic Personal Health Record

  SurvivorLink: Scalability of an Electronic Personal Health Record for Cancer Survivors and Caregivers at Pediatric Cancer Centers

• RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED INDUCTION for Adolescent and Adults

  A Phase 3, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Induction and Maintenance Study to Evaluate the Efficacy and